Novo Holdings A S Has $85.70 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Novo Holdings A S trimmed its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 21.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 750,000 shares of the company's stock after selling 200,000 shares during the quarter. Vaxcyte comprises 4.3% of Novo Holdings A S's portfolio, making the stock its 8th biggest holding. Novo Holdings A S owned about 0.67% of Vaxcyte worth $85,702,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Riverview Trust Co bought a new position in Vaxcyte in the 3rd quarter valued at $27,000. Fifth Third Bancorp bought a new position in Vaxcyte in the second quarter valued at about $35,000. Fidelis Capital Partners LLC acquired a new stake in Vaxcyte in the first quarter worth about $37,000. Blue Trust Inc. raised its holdings in Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after purchasing an additional 93 shares during the last quarter. Finally, J.Safra Asset Management Corp lifted its position in Vaxcyte by 649.4% during the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock valued at $46,000 after purchasing an additional 526 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Insider Buying and Selling

In other Vaxcyte news, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total transaction of $538,350.00. Following the completion of the transaction, the senior vice president now owns 12,723 shares in the company, valued at approximately $1,369,885.41. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of the business's stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the sale, the chief financial officer now directly owns 90,383 shares of the company's stock, valued at $10,429,294.37. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total value of $538,350.00. Following the transaction, the senior vice president now directly owns 12,723 shares of the company's stock, valued at $1,369,885.41. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 92,098 shares of company stock worth $9,937,773 over the last ninety days. Company insiders own 3.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on PCVX. BTIG Research lifted their price target on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Jefferies Financial Group lifted their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Bank of America increased their price target on Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Leerink Partners raised their price target on Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 3rd. Finally, Mizuho upped their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a report on Tuesday, September 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte has a consensus rating of "Buy" and an average target price of $147.50.

Vaxcyte Price Performance

Shares of NASDAQ PCVX traded up $0.62 during midday trading on Friday, reaching $112.94. 455,068 shares of the stock were exchanged, compared to its average volume of 829,906. Vaxcyte, Inc. has a 12 month low of $45.61 and a 12 month high of $121.06. The company has a market capitalization of $12.29 billion, a price-to-earnings ratio of -26.39 and a beta of 0.99. The business has a 50-day simple moving average of $106.09 and a two-hundred day simple moving average of $84.46.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.04. During the same period last year, the business posted ($0.70) EPS. Equities research analysts expect that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.